JNJ

168.33

+0.26%↑

NVS

117.53

+0.08%↑

ABT

128.38

+0.92%↑

MDT

92.19

-0.07%↓

ELV.US

288.71

-0.9%↓

JNJ

168.33

+0.26%↑

NVS

117.53

+0.08%↑

ABT

128.38

+0.92%↑

MDT

92.19

-0.07%↓

ELV.US

288.71

-0.9%↓

JNJ

168.33

+0.26%↑

NVS

117.53

+0.08%↑

ABT

128.38

+0.92%↑

MDT

92.19

-0.07%↓

ELV.US

288.71

-0.9%↓

JNJ

168.33

+0.26%↑

NVS

117.53

+0.08%↑

ABT

128.38

+0.92%↑

MDT

92.19

-0.07%↓

ELV.US

288.71

-0.9%↓

JNJ

168.33

+0.26%↑

NVS

117.53

+0.08%↑

ABT

128.38

+0.92%↑

MDT

92.19

-0.07%↓

ELV.US

288.71

-0.9%↓

Search

KalVista Pharmaceuticals Inc

Open

SectorHealthcare

14.01 4.32

Overview

Share price change

24h

Current

Min

13.57

Max

14.04

Key metrics

By Trading Economics

Income

-3.7M

-52M

EPS

-0.99

Employees

270

EBITDA

-1.4M

-43M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+133.38% upside

Dividends

By Dow Jones

Next Earnings

4 Sept 2025

Market Stats

By TradingEconomics

Market Cap

-71M

678M

Previous open

9.69

Previous close

14.01

News Sentiment

By Acuity

50%

50%

157 / 375 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

KalVista Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

7 Jul 2025, 11:30 UTC

Major Market Movers

KalVista Pharmaceuticals Shares Rise on FDA Approval of Hereditary Angioedema Drug

4 Nov 2024, 21:11 UTC

Major Market Movers

KalVista Pharmaceuticals Shares Rise 11% on Royalty Financing Deal, Stock Offering

Peer Comparison

Price change

KalVista Pharmaceuticals Inc Forecast

Price Target

By TipRanks

133.38% upside

12 Months Forecast

Average 31.67 USD  133.38%

High 40 USD

Low 20 USD

Based on 9 Wall Street analysts offering 12 month price targets forKalVista Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

9

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

12.19 / 12.825Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

157 / 375 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.